HAND2 and breast cancer: Conversely, in the context of PFS, an elevated HAND2-AS1 expression was significantly linked to reduced PFS rates in breast cancer, CRC, diffuse large B cell lymphoma, ovarian cancer, and pancreatic cancer (Fig. 7C).